| Davis, Molly |
NCT06353997: Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients |
|
|
| Not yet recruiting | 2 | 12 | US | Pembrolizumab, KEYTRUDA, INBRX-106 | Providence Health & Services, Inhibrx, Inc. | Triple Negative Breast Cancer | 06/26 | 06/29 | | |
NCT05249114: Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors |
|
|
| Active, not recruiting | 1 | 6 | US | Cabozantinib, Cabometyx, Lu-177, Lutathera | Providence Health & Services, Exelixis, Advanced Accelerator Applications SA | Neuroendocrine Tumors | 12/24 | 12/26 | | |
NCT06357832: New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD) |
|
|
| Recruiting | N/A | 104 | US | Brainsway Deep TMS System, Brainsway Deep TMS Device | Brainsway | Major Depressive Disorder | 12/24 | 02/25 | | |
| Seplow, Samson |
NCT06357832: New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD) |
|
|
| Recruiting | N/A | 104 | US | Brainsway Deep TMS System, Brainsway Deep TMS Device | Brainsway | Major Depressive Disorder | 12/24 | 02/25 | | |
